Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Jun 1;99(11):2752-61.
doi: 10.1172/JCI119465.

IFN-gamma potentiates atherosclerosis in ApoE knock-out mice

Affiliations

IFN-gamma potentiates atherosclerosis in ApoE knock-out mice

S Gupta et al. J Clin Invest. .

Abstract

The early colocalization of T cells and the potent immunostimulatory cytokine IFN-gamma to atherosclerotic lesions suggest that the immune system contributes to atherogenesis. Since mice with a targeted disruption of the apoE gene (apoE 0 mice) develop profound atherosclerosis, we examined the role of IFN-gamma in this process. First, the presence of CD4(+) and CD8(+) cells, which secrete lesional IFN-gamma, was documented in apoE 0 atheromata. Then, the apoE 0 mice were crossed with IFN-gamma receptor (IFNgammaR) 0 mice to generate apoE 0/IFNgammaR 0 mice. Compared to the apoE 0 mice, the compound knock-out mice exhibited a substantial reduction in atherosclerotic lesion size, a 60% reduction in lesion lipid accumulation, a decrease in lesion cellularity, but a marked increase in lesion collagen content. Evaluation of the plasma lipoproteins showed that the compound knockout mice had a marked increase in potentially atheroprotective phospholipid/apoA-IV rich particles as well. This correlated with an induction of hepatic apoA-IV transcripts. These observations suggest that IFN-gamma promotes and modifies atherosclerosis through both local effects in the arterial wall as well as a systemic effect on plasma lipoproteins. Therefore, therapeutic inhibition of IFN-gamma signaling may lead to the formation of more lipid-poor and stable atheromata.

PubMed Disclaimer

References

    1. Annu Rev Immunol. 1994;12:635-73 - PubMed
    1. Annu Rev Immunol. 1993;11:571-611 - PubMed
    1. Arteriosclerosis. 1986 Mar-Apr;6(2):131-8 - PubMed
    1. Science. 1993 Mar 19;259(5102):1739-42 - PubMed
    1. Science. 1996 Aug 16;273(5277):966-8 - PubMed

Publication types

MeSH terms